Takeda loses AMR treatment patent used in kidney transplants

Company faces setback as EPO revokes patent for a C1-esterase inhibitor treatment | Patent aims at preventing antibody-mediated rejection in kidney transplant patients | Court cites insufficient clinical trial data.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

UPC dispute resolution forum opens with ceremony in Slovenia

2 June 2026 The court has officially opened its mediation and arbitration forum, with technology, life sciences and manufacturing companies expected to be among its earliest users—particularly in FRAND and licensing cases.

Europe

European court backs AstraZeneca unit in blood cancer combo dispute

28 May 2026 A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.

Europe

Chinese medtech company fined by UPC over injunction breaches

21 May 2026 The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.

More features

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

Dehns appoints head of litigation following wave of senior hires

Chadha & Chadha hires former Remfry & Sagar patent partner

Heated LNP litigation puts Moderna and Acuitas in the spotlight

UPC dispute resolution forum opens with ceremony in Slovenia

J&J unit's valuable heart pump saved by 'rare' patent defence

Kirkland & Ellis adds leading barrister in London

Takeda loses AMR treatment patent used in kidney transplants

More on this story

Editor's picks

Editor's picks

More features